Self-assembled micelle derived from pterostilbene ameliorate acute inflammatory bowel disease

Int J Pharm. 2023 Jan 5:630:122420. doi: 10.1016/j.ijpharm.2022.122420. Epub 2022 Nov 19.

Abstract

PEGylated pterostilbene micelle (PTENPs) with higher bioavailability, biocompatibility, and water solubility were prepared. Then we detected the therapeutic effects in the treatment of inflammatory bowel disease (IBD), together with its potential mechanisms. The anti-oxidant effects and anti-inflammatory effects of PTENPs were determined under in vitro and in vivo conditions. Besides, the cellular toxicity of the PTENPs was determined in vitro, and biocompatibility testing was performed on a colitis mice model to determine its safety. The self-assembled PTENPs showed potency in treating IBD, which was featured by effectively anti-oxidant capacity, inhibition of cellular damages, and an anti-inflammatory role. In addition, PTENPs could inhibit the activation of TLR4, thereby inhibiting the NF-κB and MAPK signaling pathways. Meanwhile, it could protect colonic tissues from oxidative damage, which promoted the remission of colonic inflammation with low toxicity. Compared with free PTE, PTENPs could effectively ameliorate acute IBD with low toxicity, which may be related to the inactivation of TLR4, and inhibition of NF-κB and MAPK signaling pathways.

Keywords: Anti-inflammation; Inflammatory bowel disease; Oxidative stress; Pterostilbene micelle.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / pharmacology
  • Inflammatory Bowel Diseases* / drug therapy
  • Mice
  • Micelles
  • NF-kappa B* / metabolism
  • Signal Transduction
  • Toll-Like Receptor 4 / metabolism

Substances

  • NF-kappa B
  • pterostilbene
  • Micelles
  • Toll-Like Receptor 4
  • Anti-Inflammatory Agents
  • 3,5-dimethoxy-4'-hydroxystilbene
  • Antioxidants